As of August 7, 22 innovative drug companies have released their first-half performance reports for 2026, with a generally positive trend. Among them, 12 reported year-on-year growth, 3 turned profitable, and 1 narrowed its losses. Based on the median of semi-annual reports, performance forecasts, and preliminary results, one company saw net profit surge over 10 times, another increased by more than 5 times, and three others achieved net profit growth exceeding 100%.
The CRO sector also demonstrated strong performance. As of August 7, eight companies in the A-share CRO sector had disclosed their semi-annual reports or performance forecasts, with six of them expected to achieve double-digit or higher growth. The impressive financial results from several leading innovative drug companies in the first half of 2026 have once again captured market attention: has the innovative drug industry officially crossed the cyclical inflection point and entered a new phase of profit realization? ETFs like the Hong Kong-listed Innovation Drug ETF Yinhua (159567) and the Innovation Drug ETF Yinhua (159992) may be worth monitoring for those interested in this trend.
What are the core drivers of this performance growth?
According to institutional research reports, the significant acceleration in performance for the innovative drug and CRO sectors is primarily attributed to the convergence of four factors.
Domestic innovative drugs enter a harvest period
To understand the profitability of Chinese innovative drug companies, one must first grasp the unique nature of their business model: long R&D cycles, high investment, extremely high failure rates, but the ability to set prices during the patent period after success. Therefore, the core asset of an innovative drug company is not its current production volume, but its "pipeline" (i.e., the portfolio of new drugs at various stages of development that have not yet been approved for market launch). The industry's overall improving performance this year is an inevitable result of years of sustained investment gradually entering the harvest period. As domestic innovative product pipelines successively disclose key data, China's self-developed new drugs are being approved for market at an accelerated pace. In the first half of 2026, multiple innovative drug companies achieved sustained sales volume growth driven by blockbuster products, validating their ability to build commercial systems.
Out-licensing deals generate revenue boosts
Business development (BD) transactions for innovative drugs are currently entering a concentrated period of value realization. The upfront payments, milestone payments, and sales royalties from previously signed BD deals are set to be densely reflected in the semi-annual reports of listed companies. Upfront payments, confirmed at the time of signing, offer the highest certainty. Milestone payments are triggered gradually based on clinical progress, with timing dependent on R&D timelines. Sales royalties provide a stable source of long-term cash flow after a product is commercialized. Notably, 2025 and 2026 represent the peak period for signing BD transactions, making the 2026 semi-annual report the first major settlement point, where a significant accumulation of past upfront payments and milestone revenue will be recognized.
Order recovery in the CRO industry chain
CRO refers to contract research organizations that cover the entire drug development, production, and commercialization process. Innovative drug companies outsource certain stages to shorten R&D cycles and optimize capital allocation efficiency. Currently, the recovery of global biomedical investment and financing is injecting strong momentum into this industry. According to data from PharmaCube, global financing reached $20.177 billion in the first half of 2026, a year-on-year increase of 58.5%. Analysis suggests that overseas R&D and production outsourcing demand is steadily recovering, domestic large pharmaceutical companies are gradually increasing their annual R&D spending, and biotechnology companies are emerging from their trough. Additionally, the continued activity in out-licensing (BD) collaborations is expected to drive substantial growth in CRO R&D outsourcing demand in 2026.
Marginal easing of external industry constraints
From a policy perspective, the "15th Five-Year Plan for National Health" issued by the State Council in July provides a strong institutional guarantee for the development of innovative drugs. The plan systematically outlines measures to support the full-chain development of innovative drugs and medical devices, optimize review and approval processes, and improve the clinical comprehensive evaluation system. Analysts indicate that Chinese innovative drug companies are currently in an unprecedented golden policy period, with the industry ecosystem continuously improving, from drug regulatory review, medical insurance access, and major new drug projects to comprehensive government support policies.
Performance realization drives valuation recovery, with a catalyst-rich second half of the year
Looking ahead, some institutions suggest that innovative drugs and CRO remain key areas of focus for the entire year. From a positioning perspective, the allocation of the public healthcare sector by mutual funds in the second quarter of 2026 has fallen to historically low levels. According to relevant institutions, the heavy position ratio of actively managed equity funds (including healthcare-themed funds) in healthcare was approximately 5.94%, a relatively low level since 2010. Although overall healthcare allocation decreased in the second quarter of 2026, internal structural differentiation saw increased allocation to innovative drug and CRO sub-sectors.
From an investment logic perspective, the healthcare sector's momentum may have shifted from "early-stage oversold recovery" to being driven by "fundamentals and industry trends." With the arrival of the mid-year reporting season and expectations for innovative drug pipeline catalysts, institutions remain optimistic about the healthcare market's outlook, recommending a focus on core themes such as performance realization, order growth, pipeline data, and out-licensing validation.
The second half of 2026 is a period for the concentrated disclosure of global Phase III clinical trial data for domestic innovative drugs. International academic conferences, including the World Conference on Lung Cancer (WCLC) in August, the European Society for Medical Oncology (ESMO) congress in October, and the American Society of Hematology (ASH) annual meeting in December, will sequentially release relevant research results. Unlike earlier catalysts focused on early-stage clinical data, if the disclosed global multi-center Phase III data generally meets expectations, it could further drive overseas registration applications, milestone payment expectations, and subsequent commercialization processes.
Some institutions note that short-term volatility in the innovative drug sector may increase, but if the industry's favorable direction does not fundamentally change, and within an investor's risk tolerance, valuation corrections may offer a certain medium- to long-term allocation window for quality assets.
For those optimistic about the long-term value of the innovative drug industry, within their own risk tolerance, they can consider capturing the core A+H innovation drug sector opportunities through the Hong Kong-listed Innovation Drug ETF Yinhua (159567) and its feeder funds (Class A: 023929, Class C: 023930), as well as the Innovation Drug ETF Yinhua (159992) and its feeder funds (Class A: 012781; Class C: 012782).
Risk Warning: Investment involves risk, and caution is needed. A fund is a long-term investment tool whose main function is to diversify risk. Funds differ from financial instruments like bank deposits that provide fixed income expectations. When purchasing a fund product, you may share in the investment returns or bear losses. Before making an investment decision, please read the fund contract, prospectus, and product summary carefully. Understand the fund's risk-return characteristics and consider your own risk tolerance. Based on regulations, Yinhua Fund Management Co., Ltd. provides the following risk disclosures: Funds are categorized by investment targets, offering different return expectations and risk levels. Fund operations face various risks, including market risk, management risk, and liquidity risk. The past performance of a fund does not guarantee future results. Investors should adhere to the "buyer beware" principle.